Raras
Buscar doenças, sintomas, genes...
Doença de Charcot-Marie-Tooth intermediária
Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A doença de Charcot-Marie-Tooth (CMT), também conhecida como Neuropatia Hereditária Motora e Sensorial (NHMS), é um distúrbio neurológico hereditário que afeta os nervos periféricos responsáveis por transmitir sinais entre o cérebro, a medula espinhal e o restante do corpo.

Publicações científicas
25 artigos
Último publicado: 2026 Mar
🏥
SUS: Sem cobertura SUSScore: 0%
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

💪
Músculos
25 sintomas
🧠
Neurológico
15 sintomas
🦴
Ossos e articulações
8 sintomas
👁️
Olhos
4 sintomas
👂
Ouvidos
4 sintomas
😀
Face
2 sintomas

+ 62 sintomas em outras categorias

Características mais comuns

Espasticidade
Aumento da concentração de proteína no LCR
Morfologia anormal da pupila
Fraqueza muscular
Hipertrofia do músculo esquelético
Dismielinização periférica
124sintomas
Sem dados (124)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 124 características clínicas mais associadas, ordenadas por frequência.

EspasticidadeSpasticity
Aumento da concentração de proteína no LCRIncreased CSF protein concentration
Morfologia anormal da pupilaAbnormal pupil morphology
Fraqueza muscularMuscle weakness
Hipertrofia do músculo esqueléticoSkeletal muscle hypertrophy

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico25PubMed
Últimos 10 anos19publicações
Pico20194 papers
Linha do tempo
2026Hoje · 2026🧪 2012Primeiro ensaio clínico📈 2019Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

11 genes identificados com associação a esta condição.

INF2Inverted formin-2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Severs actin filaments and accelerates their polymerization and depolymerization

LOCALIZAÇÃO

Cytoplasm, perinuclear region

MECANISMO DE DOENÇA

Focal segmental glomerulosclerosis 5

A renal pathology defined by the presence of segmental sclerosis in glomeruli and resulting in proteinuria, reduced glomerular filtration rate and progressive decline in renal function. Renal insufficiency often progresses to end-stage renal disease, a highly morbid state requiring either dialysis therapy or kidney transplantation.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
204.3 TPM
Artéria tibial
83.2 TPM
Artéria coronária
78.6 TPM
Aorta
69.0 TPM
Brain Spinal cord cervical c-1
68.8 TPM
OUTRAS DOENÇAS (3)
Charcot-Marie-Tooth disease dominant intermediate Efocal segmental glomerulosclerosis 5familial idiopathic steroid-resistant nephrotic syndrome
HGNC:23791UniProt:Q27J81
DNM2Dynamin-2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Catalyzes the hydrolysis of GTP and utilizes this energy to mediate vesicle scission at plasma membrane during endocytosis and filament remodeling at many actin structures during organization of the actin cytoskeleton (PubMed:15731758, PubMed:19605363, PubMed:19623537, PubMed:33713620, PubMed:34744632). Plays an important role in vesicular trafficking processes, namely clathrin-mediated endocytosis (CME), exocytic and clathrin-coated vesicle from the trans-Golgi network, and PDGF stimulated macr

LOCALIZAÇÃO

Cytoplasm, cytoskeletonCytoplasmic vesicle, clathrin-coated vesicleCell projection, uropodiumEndosomeCytoplasm, cytoskeleton, microtubule organizing center, centrosomeCytoplasm, cytoskeleton, microtubule organizing center, centrosome, centrioleRecycling endosomeCell projection, phagocytic cupCytoplasmic vesicle, phagosome membraneCell projection, podosomeCytoplasmCell junctionPostsynaptic densitySynapse, synaptosomeMidbodyMembrane, clathrin-coated pit

VIAS BIOLÓGICAS (1)
NOSTRIN mediated eNOS trafficking
MECANISMO DE DOENÇA

Myopathy, centronuclear, 1

A congenital muscle disorder characterized by progressive muscular weakness and wasting involving mainly limb girdle, trunk, and neck muscles. It may also affect distal muscles. Weakness may be present during childhood or adolescence or may not become evident until the third decade of life. Ptosis is a frequent clinical feature. The most prominent histopathologic features include high frequency of centrally located nuclei in muscle fibers not secondary to regeneration, radial arrangement of sarcoplasmic strands around the central nuclei, and predominance and hypotrophy of type 1 fibers.

EXPRESSÃO TECIDUAL(Ubíquo)
Pulmão
107.7 TPM
Skin Sun Exposed Lower leg
97.2 TPM
Sangue
94.9 TPM
Intestino delgado
92.3 TPM
Baço
85.9 TPM
OUTRAS DOENÇAS (5)
fetal akinesia-cerebral and retinal hemorrhage syndromeautosomal dominant centronuclear myopathyCharcot-Marie-Tooth disease dominant intermediate Bcentronuclear myopathy
HGNC:2974UniProt:P50570
KARS1Lysine--tRNA ligaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the specific attachment of an amino acid to its cognate tRNA in a 2 step reaction: the amino acid (AA) is first activated by ATP to form AA-AMP and then transferred to the acceptor end of the tRNA (PubMed:18029264, PubMed:18272479, PubMed:9278442). When secreted, acts as a signaling molecule that induces immune response through the activation of monocyte/macrophages (PubMed:15851690). Catalyzes the synthesis of the signaling molecule diadenosine tetraphosphate (Ap4A), and thereby media

LOCALIZAÇÃO

Cytoplasm, cytosolCytoplasmNucleusCell membraneSecretedMitochondrion

VIAS BIOLÓGICAS (3)
Selenoamino acid metabolismCytosolic tRNA aminoacylationTranscriptional and post-translational regulation of MITF-M expression and activity
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, recessive intermediate B

A form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Recessive intermediate forms of Charcot-Marie-Tooth disease are characterized by clinical and pathologic features intermediate between demyelinating and axonal peripheral neuropathies, and motor median nerve conduction velocities ranging from 25 to 45 m/sec.

OUTRAS DOENÇAS (7)
autosomal recessive nonsyndromic hearing loss 89Charcot-Marie-Tooth disease recessive intermediate Bdeafness, congenital, and adult-onset progressive leukoencephalopathyleukoencephalopathy, progressive, infantile-onset, with or without deafness
HGNC:6215UniProt:Q15046
NEFLNeurofilament light polypeptideDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Neurofilaments usually contain three intermediate filament proteins: NEFL, NEFM, and NEFH which are involved in the maintenance of neuronal caliber. May additionally cooperate with the neuronal intermediate filament proteins PRPH and INA to form neuronal filamentous networks (By similarity)

LOCALIZAÇÃO

Cell projection, axonCytoplasm, cytoskeleton

VIAS BIOLÓGICAS (6)
RAF/MAP kinase cascadeRas activation upon Ca2+ influx through NMDA receptorUnblocking of NMDA receptors, glutamate binding and activationLong-term potentiationNegative regulation of NMDA receptor-mediated neuronal transmission
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, demyelinating, type 1F

A dominant demyelinating form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Demyelinating neuropathies are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet. CMT1F is characterized by onset in infancy or childhood (range 1 to 13 years).

EXPRESSÃO TECIDUAL(Tecido-específico)
Brain Frontal Cortex BA9
487.2 TPM
Córtex cerebral
328.6 TPM
Brain Anterior cingulate cortex BA24
195.3 TPM
Hipotálamo
136.9 TPM
Substância negra
100.6 TPM
OUTRAS DOENÇAS (4)
Charcot-Marie-Tooth disease type 1FCharcot-Marie-Tooth disease, dominant intermediate GCharcot-Marie-Tooth disease type 2ECharcot-Marie-Tooth disease type 2B5
HGNC:7739UniProt:P07196
COX6A1Cytochrome c oxidase subunit 6A1, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the cytochrome c oxidase, the last enzyme in the mitochondrial electron transport chain which drives oxidative phosphorylation. The respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase (complex IV, CIV), that cooperate to transfer electrons derived from NADH and succinate to molecular oxygen, creating an electrochemical gradient over t

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (4)
Cytoprotection by HMOX1Respiratory electron transportTP53 Regulates Metabolic GenesComplex IV assembly
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, recessive intermediate D

A form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Recessive intermediate forms of Charcot-Marie-Tooth disease are characterized by clinical and pathologic features intermediate between demyelinating and axonal peripheral neuropathies, and motor median nerve conduction velocities ranging from 25 to 45 m/sec.

OUTRAS DOENÇAS (1)
Charcot-Marie-Tooth disease recessive intermediate D
HGNC:2277UniProt:P12074
GBF1Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Guanine-nucleotide exchange factor (GEF) for members of the Arf family of small GTPases involved in trafficking in the early secretory pathway; its GEF activity initiates the coating of nascent vesicles via the localized generation of activated ARFs through replacement of GDP with GTP. Recruitment to cis-Golgi membranes requires membrane association of Arf-GDP and can be regulated by ARF1, ARF3, ARF4 and ARF5. Involved in the recruitment of the COPI coat complex to the endoplasmic reticulum exit

LOCALIZAÇÃO

Golgi apparatus, cis-Golgi networkEndoplasmic reticulum-Golgi intermediate compartmentGolgi apparatus, trans-Golgi networkGolgi apparatusCytoplasmLipid dropletMembrane

VIAS BIOLÓGICAS (3)
COPI-mediated anterograde transportDengue Virus-Host InteractionsCOPI-dependent Golgi-to-ER retrograde traffic
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, axonal, type 2GG

An axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. CMT2GG is an autosomal dominant form characterized by slowly progressive distal muscle weakness and atrophy primarily affecting the lower limbs and causing difficulty walking. Some individuals may also have involvement of the hands.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
70.4 TPM
Cerebelo
66.7 TPM
Tireoide
66.5 TPM
Útero
60.7 TPM
Cervix Endocervix
58.4 TPM
OUTRAS DOENÇAS (1)
Charcot-Marie-Tooth Disease, axonal, type 2GG
HGNC:HGNC:4181UniProt:Q92538
PLEKHG5Pleckstrin homology domain-containing family G member 5Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Functions as a guanine exchange factor (GEF) for RAB26 and thus regulates autophagy of synaptic vesicles in axon terminal of motoneurons (By similarity). Involved in the control of neuronal cell differentiation (PubMed:11704860). Plays a role in angiogenesis through regulation of endothelial cells chemotaxis. Also affects the migration, adhesion, and matrix/bone degradation in macrophages and osteoclasts (PubMed:23777631)

LOCALIZAÇÃO

CytoplasmCytoplasm, perinuclear regionCell membraneCell junctionCell projection, lamellipodium

VIAS BIOLÓGICAS (5)
G alpha (12/13) signalling eventsNRAGE signals death through JNKRND1 GTPase cycleRND3 GTPase cycleRHOA GTPase cycle
MECANISMO DE DOENÇA

Neuronopathy, distal hereditary motor, autosomal recessive 4

A form of distal hereditary motor neuronopathy, a heterogeneous group of neuromuscular disorders caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs. HMNR4 is characterized by childhood onset, generalized muscle weakness and atrophy with denervation and normal sensation. Bulbar symptoms and pyramidal signs are absent.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
244.8 TPM
Cérebro - Hemisfério cerebelar
198.3 TPM
Skin Not Sun Exposed Suprapubic
118.5 TPM
Skin Sun Exposed Lower leg
101.4 TPM
Baço
78.8 TPM
INTERAÇÕES PROTEICAS (3)
OUTRAS DOENÇAS (2)
Charcot-Marie-Tooth disease recessive intermediate Cneuronopathy, distal hereditary motor, autosomal recessive 4
HGNC:29105UniProt:O94827
GDAP1Ganglioside-induced differentiation-associated protein 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Regulates the mitochondrial network by promoting mitochondrial fission

LOCALIZAÇÃO

Mitochondrion outer membraneCytoplasm

VIAS BIOLÓGICAS (1)
Class I peroxisomal membrane protein import
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, demyelinating, type 4A

A recessive demyelinating form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Demyelinating neuropathies are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet. By convention autosomal recessive forms of demyelinating Charcot-Marie-Tooth disease are designated CMT4. CMT4A is a severe form characterized by early age of onset and rapid progression leading to inability to walk in late childhood or adolescence.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
80.1 TPM
Brain Frontal Cortex BA9
56.7 TPM
Cerebelo
56.0 TPM
Pituitária
40.1 TPM
Brain Anterior cingulate cortex BA24
37.6 TPM
OUTRAS DOENÇAS (6)
Charcot-Marie-Tooth disease type 4ACharcot-Marie-Tooth disease, axonal, with vocal cord paresis, autosomal recessiveCharcot-Marie-Tooth disease recessive intermediate ACharcot-Marie-Tooth disease axonal type 2K
HGNC:15968UniProt:Q8TB36
MPZMyelin protein P0Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Is an adhesion molecule necessary for normal myelination in the peripheral nervous system. It mediates adhesion between adjacent myelin wraps and ultimately drives myelin compaction

LOCALIZAÇÃO

Cell membraneMyelin membrane

VIAS BIOLÓGICAS (1)
EGR2 and SOX10-mediated initiation of Schwann cell myelination
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, demyelinating, type 1B

A dominant demyelinating form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Demyelinating neuropathies are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
5300.7 TPM
Cólon sigmoide
34.0 TPM
Esôfago - Junção
31.7 TPM
Esôfago - Muscular
30.5 TPM
Artéria coronária
19.6 TPM
OUTRAS DOENÇAS (9)
Roussy-Levy syndromeneuropathy, congenital hypomyelinating, 2Charcot-Marie-Tooth disease dominant intermediate DCharcot-Marie-Tooth disease type 2I
HGNC:7225UniProt:P25189
YARS1Tyrosine--tRNA ligase, cytoplasmicDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Tyrosine--tRNA ligase that catalyzes the attachment of tyrosine to tRNA(Tyr) in a two-step reaction: tyrosine is first activated by ATP to form Tyr-AMP and then transferred to the acceptor end of tRNA(Tyr) (Probable) (PubMed:25533949). Also acts as a positive regulator of poly-ADP-ribosylation in the nucleus, independently of its tyrosine--tRNA ligase activity (PubMed:25533949). Activity is switched upon resveratrol-binding: resveratrol strongly inhibits the tyrosine--tRNA ligase activity and pr

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (1)
Cytosolic tRNA aminoacylation
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, dominant intermediate C

A form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. The dominant intermediate type C is characterized by clinical and pathologic features intermediate between demyelinating and axonal peripheral neuropathies, and motor median nerve conduction velocities ranging from 25 to 45 m/sec.

OUTRAS DOENÇAS (2)
neurologic, endocrine, and pancreatic disease, multisystem, infantile-onset 2Charcot-Marie-Tooth disease dominant intermediate C
HGNC:12840UniProt:P54577
GNB4Guanine nucleotide-binding protein subunit beta-4Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Guanine nucleotide-binding proteins (G proteins) are involved as a modulator or transducer in various transmembrane signaling systems. The beta and gamma chains are required for the GTPase activity, for replacement of GDP by GTP, and for G protein-effector interaction

LOCALIZAÇÃO

VIAS BIOLÓGICAS (10)
Extra-nuclear estrogen signalingGPER1 signalingThromboxane signalling through TP receptorADORA2B mediated anti-inflammatory cytokines productionProstacyclin signalling through prostacyclin receptor
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, dominant intermediate F

A form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. CMTDIF is characterized by onset around adolescence of slowly progressive distal muscle atrophy and weakness affecting the upper and lower limbs and resulting in steppage gait. There is distal sensory impairment with decreased reflexes. Nerve conduction velocities are variable, ranging from the demyelinating to the axonal range.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
43.9 TPM
Aorta
29.5 TPM
Skin Not Sun Exposed Suprapubic
27.7 TPM
Skin Sun Exposed Lower leg
26.6 TPM
Esôfago - Muscular
25.8 TPM
OUTRAS DOENÇAS (1)
Charcot-Marie-Tooth disease dominant intermediate F
HGNC:20731UniProt:Q9HAV0

Variantes genéticas (ClinVar)

503 variantes patogênicas registradas no ClinVar.

🧬 INF2: GRCh37/hg19 14q32.2-32.33(chr14:97521552-107285437)x3 ()
🧬 INF2: GRCh37/hg19 14q32.2-32.33(chr14:101180490-106329074)x1 ()
🧬 INF2: NM_022489.4(INF2):c.3706G>T (p.Asp1236Tyr) ()
🧬 INF2: NM_022489.4(INF2):c.604A>C (p.Asn202His) ()
🧬 INF2: NM_022489.4(INF2):c.529C>G (p.Arg177Gly) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 3 variantes classificadas pelo ClinVar.

1
2
Patogênica (33.3%)
VUS (66.7%)
VARIANTES MAIS SIGNIFICATIVAS
CLCN1: NM_000083.3(CLCN1):c.1437_1450del (p.Pro480fs) [Pathogenic/Likely pathogenic]
SH3TC2: NM_024577.4(SH3TC2):c.3292A>C (p.Thr1098Pro) [Uncertain significance]
IGHMBP2: NM_002180.3(IGHMBP2):c.1924T>C (p.Tyr642His) [Uncertain significance]

Vias biológicas (Reactome)

67 vias biológicas associadas aos genes desta condição.

Toll Like Receptor 4 (TLR4) Cascade Retrograde neurotrophin signalling Gap junction degradation Formation of annular gap junctions NOSTRIN mediated eNOS trafficking MHC class II antigen presentation Lysosome Vesicle Biogenesis Golgi Associated Vesicle Biogenesis Recycling pathway of L1 Clathrin-mediated endocytosis NGF-stimulated transcription Degradation of CDH1 Selenoamino acid metabolism Cytosolic tRNA aminoacylation Mitochondrial tRNA aminoacylation Transcriptional and post-translational regulation of MITF-M expression and activity Unblocking of NMDA receptors, glutamate binding and activation Ras activation upon Ca2+ influx through NMDA receptor RAF/MAP kinase cascade Assembly and cell surface presentation of NMDA receptors Negative regulation of NMDA receptor-mediated neuronal transmission Long-term potentiation TP53 Regulates Metabolic Genes Respiratory electron transport Cytoprotection by HMOX1 Complex IV assembly trans-Golgi Network Vesicle Budding VxPx cargo-targeting to cilium COPI-mediated anterograde transport COPI-dependent Golgi-to-ER retrograde traffic Assembly and Release of Dengue Virus Virions Dengue Virus-Host Interactions NRAGE signals death through JNK G alpha (12/13) signalling events RHOA GTPase cycle RND3 GTPase cycle RND1 GTPase cycle Class I peroxisomal membrane protein import EGR2 and SOX10-mediated initiation of Schwann cell myelination Activation of G protein gated Potassium channels Glucagon signaling in metabolic regulation G-protein activation Glucagon-like Peptide-1 (GLP1) regulates insulin secretion ADP signalling through P2Y purinoceptor 12 G beta:gamma signalling through PI3Kgamma Prostacyclin signalling through prostacyclin receptor Adrenaline,noradrenaline inhibits insulin secretion Ca2+ pathway G alpha (q) signalling events G beta:gamma signalling through PLC beta G alpha (s) signalling events ADP signalling through P2Y purinoceptor 1 G alpha (i) signalling events G alpha (z) signalling events Glucagon-type ligand receptors Thromboxane signalling through TP receptor Vasopressin regulates renal water homeostasis via Aquaporins Thrombin signalling through proteinase activated receptors (PARs) Presynaptic function of Kainate receptors Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding G beta:gamma signalling through BTK G beta:gamma signalling through CDC42 Extra-nuclear estrogen signaling GPER1 signaling ADORA2B mediated anti-inflammatory cytokines production High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
·Pré-clínico5
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 5 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Doença de Charcot-Marie-Tooth intermediária

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

2 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

0 ensaios clínicos encontrados.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
19 papers (10 anos)
#1

Novel Biallelic PLEKHG5 Variant Associated With Intermediate Charcot-Marie-Tooth Disease: Case Report From South America.

Journal of the peripheral nervous system : JPNS2026 Mar

Biallelic pathogenic variants in PLEKHG5 are associated with two distinct recessive phenotypes, including distal hereditary motor neuropathy AR type 4 and intermediate Charcot-Marie-Tooth disease type C (CMT). No South American cases have been previously reported. We evaluated a male patient with suspected hereditary neuropathy using clinical, electrophysiological, and genetic studies. Symptoms began at 12 years with progressive distal weakness. At 40 years, he had foot drop, pes cavus, distal atrophy, areflexia, and sensory loss to the knees. Disability scales indicated moderate impairment. Electroneuromyography revealed abolished responses in the lower limbs and motor conduction velocities in the intermediate range (35-40 m/s). Genetic analysis identified the homozygous variant c.59G>A (p.Arg20Gln) in PLEKHG5, currently classified as VUS. This reports presents a case from South American linking a homozygous PLEKHG5 variant to recessive intermediate CMT, expanding the geographic and phenotypic spectrum of PLEKHG5-related neuropathies.

#2

ITPR3-associated neuropathy: Report of a further family with adult onset intermediate Charcot-Marie-Tooth disease.

European journal of neurology2024 Dec

ITPR3 encodes type 3 inositol-tri-phosphate receptor (IP3R3), a protein expressed in Schwann cells, predominantly in the paranodal region, and involved in the regulation of Ca2+ release from the endoplasmic reticulum. Dominant variants in ITPR3 have recently been recognized as a rare cause of intermediate Charcot-Marie-Tooth disease (CMT). We collected the clinical data of a family with autosomal dominant neuropathy whose proband was diagnosed with chronic inflammatory demyelinating polyneuropathy (CIDP) for many years. The genetic diagnosis was achieved by whole exome sequencing. The proband developed symmetrical sensory-motor neuropathy with demyelinating features at 32 years old. He was diagnosed with CIDP and received numerous immunomodulatory treatments. However, his condition progressed, leading to severe proximal leg and hand atrophy that confined him to a wheelchair at 60 years. The patient's two sons began to exhibit symptoms suggestive of neuropathy shortly after age 30 years, and the condition was reoriented as inherited. Exome sequencing identified a heterozygous c.4271C > T variant in the ITPR3 gene segregating with the disease. Nerve conduction studies showed a combination of demyelinating and axonal features that vary by nerve, disease duration, and patient. A uniform thickening of the nerves was identified on nerve echography, as was distal symmetric fatty infiltration in lower limb muscle imaging. The c.4271C > T ITPR3 variant causes a late onset CMT that can be considered an intermediate CMT. Considering the electrophysiological findings and the distribution of IP3R3, we hypothesize that this variant could start as nodal dysfunction that progresses to widespread nerve degeneration.

#3

Correction to: C1orf194 deficiency leads to incomplete early embryonic lethality and dominant intermediate Charcot-Marie-Tooth disease in a knockout mouse model.

Human molecular genetics2024 Jun 05
#4

A novel single-point mutation of NEFH and biallelic SACS mutation presenting as intermediate form Charcot-Marie-Tooth: A case report in Vietnam.

Surgical neurology international2022

Charcot-Marie-Tooth disease (CMT) is among the most common group of inherited neuromuscular diseases. SACS mutations were demonstrated to cause autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS). However, there have been few case reports regarding to NEFH and SACS gene mutation to CMT in Vietnamese patients, and the diagnosis of CMT and ARSACS in the clinical setting still overlapped. We report two patients presenting with sensorimotor neuropathy without cerebellar ataxia, spasticity and other neurological features, being diagnosed with intermediate form CMT by electrophysiological and clinical examination and neuroimaging. By whole-exome sequencing panel of two affected members, and PCR Sanger on NEFH and SACS genes to confirm the presence of selected variants on their parents, we identified a novel missense variant NEFH c.1925C>T (inherited from the mother) in an autosomal dominant heterozygous state, and two recessive SACS variants (SACS c.13174C>T, causing missense variant, and SACS c.11343del, causing frameshift variant) (inherited one from the mother and another from the father) in these two patients. Clinical and electrophysiological findings on these patients did not match classical ARSACS. To the best of our knowledge, this is the first case report of two affected siblings diagnosed with CMT carrying both a novel NEFH variant and biallelic SACS variants. We concluded that this novel NEFH variant is likely benign, and biallelic SACS mutation (c.13174C>T and c.11343del) is likely pathogenic for intermediate form CMT. This study is also expected to emphasize the current knowledge of intermediate form CMT, ARSACS, and the phenotypic spectrum of NEFH-related and SACS-related disorders. We expect to give a new understanding of CMT; however, further research should be conducted to provide a more thorough knowledge of the pathogenesis of CMT in the future.

#5

Homozygous N-terminal missense variant in PLEKHG5 associated with intermediate CMT: A case report.

Journal of neuromuscular diseases2022

Mutations in PLEKHG5, a pleckstrin homology domain containing member of the GEF family, are associated with distal spinal muscular atrophy and intermediate Charcot-Marie-Tooth disease. Here, we describe an isolated case with distal intermediate neuropathy with scapular winging. By whole exome sequencing, we identified the homozygous PLEKHG5 Arg97Gln missense mutation, located in the N-terminal region of the protein. This mutation resides between a zinc-finger motif and a RBD domain, involved in binding rnd3, a RhoA effector protein. We conclude that based on the characteristic phenotype presented by the patient and the supportive genetic findings, the PLEKHG5 mutation is the causative variant.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC21 artigos no totalmostrando 18

2026

Novel Biallelic PLEKHG5 Variant Associated With Intermediate Charcot-Marie-Tooth Disease: Case Report From South America.

Journal of the peripheral nervous system : JPNS
2024

ITPR3-associated neuropathy: Report of a further family with adult onset intermediate Charcot-Marie-Tooth disease.

European journal of neurology
2022

A novel single-point mutation of NEFH and biallelic SACS mutation presenting as intermediate form Charcot-Marie-Tooth: A case report in Vietnam.

Surgical neurology international
2022

Homozygous N-terminal missense variant in PLEKHG5 associated with intermediate CMT: A case report.

Journal of neuromuscular diseases
2022

Precision mouse models of Yars/dominant intermediate Charcot-Marie-Tooth disease type C and Sptlc1/hereditary sensory and autonomic neuropathy type 1.

Journal of anatomy
2021

Leukoencephalopathy and conduction blocks in PLEKHG5-associated intermediate CMT disease.

Neuromuscular disorders : NMD
2021

Novel variants broaden the phenotypic spectrum of PLEKHG5-associated neuropathies.

European journal of neurology
2020

C1orf194 deficiency leads to incomplete early embryonic lethality and dominant intermediate Charcot-Marie-Tooth disease in a knockout mouse model.

Human molecular genetics
2019

[Analysis of a pedigree with autosomal dominant intermediate Charcot-Marie-Tooth disease type E and nephropathy].

Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
2019

ATP1A1 mutations cause intermediate Charcot-Marie-Tooth disease.

Human mutation
2019

Novel GARS mutation presenting as autosomal dominant intermediate Charcot-Marie-Tooth disease: Intermediate or axonal?

Journal of the peripheral nervous system : JPNS
2019

Novel GARS mutation presenting as autosomal dominant intermediate Charcot-Marie-Tooth disease.

Journal of the peripheral nervous system : JPNS
2017

A novel missense variant (Gln220Arg) of GNB4 encoding guanine nucleotide-binding protein, subunit beta-4 in a Japanese family with autosomal dominant motor and sensory neuropathy.

European journal of medical genetics
2017

Anatomical distributional defects in mutant genes associated with dominant intermediate Charcot-Marie-Tooth disease type C in an adenovirus-mediated mouse model.

Neural regeneration research
2017

Intermediate Charcot-Marie-Tooth disease: an electrophysiological reappraisal and systematic review.

Journal of neurology
2016

NEFL N98S mutation: another cause of dominant intermediate Charcot-Marie-Tooth disease with heterogeneous early-onset phenotype.

Journal of neurology
2016

Variants in the genes DCTN2, DNAH10, LRIG3, and MYO1A are associated with intermediate Charcot-Marie-Tooth disease in a Norwegian family.

Acta neurologica Scandinavica
2015

NEFL E396K mutation is associated with a novel dominant intermediate Charcot-Marie-Tooth disease phenotype.

Journal of neurology
Ver todos os 21 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Doença de Charcot-Marie-Tooth intermediária.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Doença de Charcot-Marie-Tooth intermediária

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Novel Biallelic PLEKHG5 Variant Associated With Intermediate Charcot-Marie-Tooth Disease: Case Report From South America.
    Journal of the peripheral nervous system : JPNS· 2026· PMID 41562385mais citado
  2. ITPR3-associated neuropathy: Report of a further family with adult onset intermediate Charcot-Marie-Tooth disease.
    European journal of neurology· 2024· PMID 39287469mais citado
  3. Correction to: C1orf194 deficiency leads to incomplete early embryonic lethality and dominant intermediate Charcot-Marie-Tooth disease in a knockout mouse model.
    Human molecular genetics· 2024· PMID 38668692mais citado
  4. A novel single-point mutation of NEFH and biallelic SACS mutation presenting as intermediate form Charcot-Marie-Tooth: A case report in Vietnam.
    Surgical neurology international· 2022· PMID 36600740mais citado
  5. Homozygous N-terminal missense variant in PLEKHG5 associated with intermediate CMT: A case report.
    Journal of neuromuscular diseases· 2022· PMID 34897098mais citado

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:476123(Orphanet)
  2. MONDO:0018778(MONDO)
  3. GARD:21954(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q18553298(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Doença de Charcot-Marie-Tooth intermediária
Compêndio · Raras BR

Doença de Charcot-Marie-Tooth intermediária

ORPHA:476123 · MONDO:0018778
CID-11
MedGen
UMLS
C5680108
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades